Ningning Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ningning Ren has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Guojun Wu
3 shared publications- Guojun Wu
Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China; Department of Breast and Thyroid Surgery, Shandong Provincial ENT Hospital Affiliated to Shandong University, Jinan 250022, China
3 shared publications Xiao Chen
2 shared publicationsXiaoyi Ren
2 shared publicationsZhigang Yao
2 shared publications- Chong Geng
Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
1 shared publication
Latest Publications
- Open Access
- 8 April 2026
- Published by Elsevier in Asian Journal of Surgery
Breast papillary carcinoma with mucinous carcinoma: A diagnostic and therapeutic challenge
- 8 April 2026
- Published by Elsevier in Asian Journal of Surgery
Open AccessBreast papillary carcinoma with mucinous carcinoma: A diagnostic and therapeutic challenge
- Open Access
- 7 April 2026
- Published by Elsevier in Asian Journal of Surgery
Metaplastic breast carcinoma with multiple differentiations: Spindle cell, squamous and chondroid components
- 7 April 2026
- Published by Elsevier in Asian Journal of Surgery
Open AccessMetaplastic breast carcinoma with multiple differentiations: Spindle cell, squamous and chondroid components
- Open Access
- 3 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (14) , e48207
Evaluation of adverse event profiles for leuprolide and goserelin: Insights from the FDA adverse event reporting system following STROBE guidelines
Leuprolide and Goserelin, both gonadotropin-releasing hormone (GnRH) agonists, are commonly used for ovarian function suppression and the management of hormone-dependent cancers. However, systematic comparisons of their adverse event (AE) profiles based on real-world pharmacovigilance data remains limited. This study aimed to compare the safety signals associated with Leuprolide and Goserelin using the the U.S. Food and Drug Administration AE Reporting System (FAERS), thereby providing insights into their distinct AE patterns. Food and Drug Administration Adverse Event Reporting System reports from the first quarter of 2004 to the third quarter of 2024 were extracted and standardized. Disproportionality signal detection was performed using the reporting odds ratio, proportional reporting ratio, chi-square (χ 2 ) test, and Bayesian confidence propagation neural network. Significant signals were defined as reporting odds ratio lower 95% CI >1, proportional reporting ratio ≥2 with χ 2 ≥4, or Bayesian confidence propagation neural network information component (IC)-2SD >0. Key signals were compared between Leuprolide- and Goserelin-related reports. A total of 12,418,989 AE reports were identified, including 64,324 Leuprolide-related and 4253 Goserelin-related cases. Both drugs showed strong signals for “prostatic specific antigen increased” (Leuprolide: χ 2 = 84,009.65, IC-2SD = 5.42; Goserelin: χ 2 = 820.31, IC-2SD = 3.38), “blood testosterone increased” (Leuprolide: χ 2 = 22,845.52, IC-2SD = 5.56; Goserelin: χ 2 = 290.23, IC-2SD = 2.28), and “prostatic specific antigen abnormal” (Leuprolide: χ 2 = 51,615.98, IC-2SD = 6.46; Goserelin: χ 2 = 422.43, IC-2SD = 2.16). Additional strong signals, such as “prostate cancer metastatic” and “hot flush,” were consistently detected in both groups. Notably, the distribution of AEs differed between drugs, suggesting drug-specific safety patterns. Leuprolide demonstrated strong associations with AEs in “Reproductive system and breast disorders,” “Neoplastic benign and malignant conditions,” and procedure-related categories, whereas Goserelin was more strongly linked to “Endocrine disorders.” These findings highlight distinct pharmacovigilance profiles between the 2 drugs and provide clinically relevant evidence to support individualized risk monitoring in hormone-dependent cancer therapies.
- 3 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (14) , e48207
Open AccessEvaluation of adverse event profiles for leuprolide and goserelin: Insights from the FDA adverse event reporting system following STROBE guidelines
Leuprolide and Goserelin, both gonadotropin-releasing hormone (GnRH) agonists, are commonly used for ovarian function suppression and the management of hormone-dependent cancers. However, systematic comparisons of their adverse event (AE) profiles based on real-world pharmacovigilance data remains limited. This study aimed to compare the safety signals associated with Leuprolide and Goserelin using the the U.S. Food and Drug Administration AE Reporting System (FAERS), thereby providing insights into their distinct AE patterns. Food and Drug Administration Adverse Event Reporting System reports from the first quarter of 2004 to the third quarter of 2024 were extracted and standardized. Disproportionality signal detection was performed using the reporting odds ratio, proportional reporting ratio, chi-square (χ 2 ) test, and Bayesian confidence propagation neural network. Significant signals were defined as reporting odds ratio lower 95% CI >1, proportional reporting ratio ≥2 with χ 2 ≥4, or Bayesian confidence propagation neural network information component (IC)-2SD >0. Key signals were compared between Leuprolide- and Goserelin-related reports. A total of 12,418,989 AE reports were identified, including 64,324 Leuprolide-related and 4253 Goserelin-related cases. Both drugs showed strong signals for “prostatic specific antigen increased” (Leuprolide: χ 2 = 84,009.65, IC-2SD = 5.42; Goserelin: χ 2 = 820.31, IC-2SD = 3.38), “blood testosterone increased” (Leuprolide: χ 2 = 22,845.52, IC-2SD = 5.56; Goserelin: χ 2 = 290.23, IC-2SD = 2.28), and “prostatic specific antigen abnormal” (Leuprolide: χ 2 = 51,615.98, IC-2SD = 6.46; Goserelin: χ 2 = 422.43, IC-2SD = 2.16). Additional strong signals, such as “prostate cancer metastatic” and “hot flush,” were consistently detected in both groups. Notably, the distribution of AEs differed between drugs, suggesting drug-specific safety patterns. Leuprolide demonstrated strong associations with AEs in “Reproductive system and breast disorders,” “Neoplastic benign and malignant conditions,” and procedure-related categories, whereas Goserelin was more strongly linked to “Endocrine disorders.” These findings highlight distinct pharmacovigilance profiles between the 2 drugs and provide clinically relevant evidence to support individualized risk monitoring in hormone-dependent cancer therapies.
- Open Access
- 9 October 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 49 (3) , 1727-1729
Hyperfunctioning papillary thyroid carcinoma: Clinical implications of preserved sodium/iodide symporter function
- 9 October 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 49 (3) , 1727-1729
Open AccessHyperfunctioning papillary thyroid carcinoma: Clinical implications of preserved sodium/iodide symporter function
- Open Access
- 25 May 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (11) , 6960-6962
Diagnosis and management of clinical occult thyroid cancer
- 25 May 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (11) , 6960-6962
Open AccessDiagnosis and management of clinical occult thyroid cancer
- Open Access
- 26 March 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (9) , 5506-5508
Management of thyroid cancer in pregnancy
- 26 March 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (9) , 5506-5508
Open AccessManagement of thyroid cancer in pregnancy
- Open Access
- 7 February 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (6) , 3749-3751
Colorectal cancer metastasizing to the thyroid: A case report and literature review
- 7 February 2025
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (6) , 3749-3751
Open AccessColorectal cancer metastasizing to the thyroid: A case report and literature review
- Open Access
- 16 February 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (7) , e37246
Postoperative recurrence of diffuse sclerosing thyroid cancer in an adolescent patient: A case report
Background: Papillary thyroid cancer is an inert malignant tumor with a good response to surgical treatment, low recurrence and metastasis rate, and good prognosis. Diffuse sclerosing thyroid cancer is an invasive subtype that is more common in young people, with a higher rate of lymph node metastasis and recurrence, and a relatively poor prognosis. Patient concerns: A 13-year-old girl underwent radical surgery for diffuse sclerosing thyroid cancer. Eight years later, due to a large number of lymph node metastases, she underwent another radical surgery on her neck lymph nodes. Methods: The patient thyroid ultrasound and neck enhanced CT indicated that the patient had multiple enlarged lymph nodes in the neck with irregular morphology and structure, and the possibility of metastatic lymph nodes was high. Subsequently, the patient underwent thyroid fine-needle aspiration and the results showed that cancer cells were detected in both cervical lymph nodes. Diagnosis: The patient was diagnosed with bilateral cervical lymph node metastases after thyroid surgery. Results: After the second surgery, the patient recovered well, and no residual or focal iodine uptake tissue was found on the enhanced CT examination. Conclusion: As diffuse sclerosing thyroid cancer is prone to lymph node and recurrent metastases, once it is diagnosed, radical treatment should be actively performed. Postoperative adjuvant radiation therapy should be administered according to the patient condition and regular follow-ups should be conducted to monitor neck lymph node metastasis.
- 16 February 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (7) , e37246
Open AccessPostoperative recurrence of diffuse sclerosing thyroid cancer in an adolescent patient: A case report
Background: Papillary thyroid cancer is an inert malignant tumor with a good response to surgical treatment, low recurrence and metastasis rate, and good prognosis. Diffuse sclerosing thyroid cancer is an invasive subtype that is more common in young people, with a higher rate of lymph node metastasis and recurrence, and a relatively poor prognosis. Patient concerns: A 13-year-old girl underwent radical surgery for diffuse sclerosing thyroid cancer. Eight years later, due to a large number of lymph node metastases, she underwent another radical surgery on her neck lymph nodes. Methods: The patient thyroid ultrasound and neck enhanced CT indicated that the patient had multiple enlarged lymph nodes in the neck with irregular morphology and structure, and the possibility of metastatic lymph nodes was high. Subsequently, the patient underwent thyroid fine-needle aspiration and the results showed that cancer cells were detected in both cervical lymph nodes. Diagnosis: The patient was diagnosed with bilateral cervical lymph node metastases after thyroid surgery. Results: After the second surgery, the patient recovered well, and no residual or focal iodine uptake tissue was found on the enhanced CT examination. Conclusion: As diffuse sclerosing thyroid cancer is prone to lymph node and recurrent metastases, once it is diagnosed, radical treatment should be actively performed. Postoperative adjuvant radiation therapy should be administered according to the patient condition and regular follow-ups should be conducted to monitor neck lymph node metastasis.